Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Lumiracoxib news from EULAR

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Dutta D, Huels J, Litschig S.Lumiracoxib is cost-effective and improves health-related quality of life in patients with osteoarthritis. 2007 Annual European Congress of Rheumatology: abstr. THU0435, 13 Jun 2007

    2. 2.

      Doan QV, Dubois RW, Omar M, Huels J.A financial impact assessment of introducing lumiracoxib onto the formulary of the UK National Health Service for the management of patients with osteoarthritis. 2007 Annual European Congress of Rheumatology: abstr. THU0433, 13 Jun 2007

    3. 3.

      Doan QV, Dubois RW, Omar M, Huels J.Comparison of the cost-effectiveness of lumiracoxib in patients with and without a history of gastrointestinal ulcer or bleed for the management of osteoarthritis. 2007 Annual European Congress of Rheumatology: abstr. THU0434, 13 Jun 2007

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Lumiracoxib news from EULAR. Pharmacoecon. Outcomes News 533, 4 (2007). https://doi.org/10.1007/BF03296121

    Download citation

    Keywords

    • Ibuprofen
    • Celecoxib
    • Proton Pump Inhibitor
    • Naproxen
    • Traditional Nsaid